Press releases
- Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
- Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
- Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
- FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain
- Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
- Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
More ▼
Key statistics
On Monday, Innocan Pharma Corp (IP4:FRA) closed at 0.165, 31.58% above the 52 week low of 0.1254 set on Jul 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1585 |
---|---|
High | 0.165 |
Low | 0.1585 |
Bid | -- |
Offer | -- |
Previous close | 0.165 |
Average volume | 139.31k |
---|---|
Shares outstanding | 275.95m |
Free float | 207.90m |
P/E (TTM) | -- |
Market cap | 63.59m CAD |
EPS (TTM) | -0.027 CAD |
Data delayed at least 15 minutes, as of Jul 08 2024 20:00 BST.
More ▼